Barrick Mining Corporation Stock Price, News & Analysis

Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).

The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.

Hexagon (B) and Management Controls announced general availability of the EcoSys + myTrack Connector, integrating EcoSys Enterprise Project Performance with MCi myTrack contractor data via EcoSys Connect.

The connector delivers real-time, verified contractor actuals into EcoSys—including labor, equipment, and materials—for STOs and capital projects, automating contractor cost flows, eliminating manual reconciliations, enabling force reporting, improving forecasting accuracy, accelerating project closeouts, and reducing financial leakage. Implementation support is available worldwide in partnership with FTI Consulting.

BioArctic (NASDAQ: B) announced that partner Eisai received a Notice of Compliance with Conditions (NOC/c) from Health Canada for Leqembi (lecanemab) on October 27, 2025, authorizing use in adults with early Alzheimer’s disease who are ApoE ε4 non-carriers or heterozygotes and have confirmed amyloid pathology.

Leqembi is described as the first treatment targeting an underlying cause of early AD and shown in the Phase 3 Clarity AD study to slow cognitive and functional decline; it is approved in 51 countries and regions. The Canadian authorization is conditional pending confirmatory trials and Eisai will submit real-world clinical assessment data. BioArctic retains Nordic commercialization rights and plans joint regional commercialization with Eisai.

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.

Barrick (NYSE:B) will report third quarter 2025 results on Monday, November 10, 2025, with the release timed for 6:00 AM ET. Management will host a live webcast presentation at 11:00 AM ET the same day followed by a Q&A with analysts. Presentation materials will be posted on the company website and a recording of the webcast will be available for replay later on November 10.

BioArctic (NASDAQ: BIOA) partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October 6, 2025 as a maintenance option for early Alzheimer’s disease (MCI or mild dementia) after an initial 18-month IV induction.

After 18 months of 10 mg/kg IV every two weeks, patients may continue IV every four weeks or switch to a weekly 360 mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education, financial/insurance support, an injection tracker and an app. Full prescribing information and a boxed warning apply.

B (Barrick) agreed to sell its interests in the Tongon gold mine and related exploration permits in Côte d’Ivoire to Atlantic for up to $305 million. The consideration comprises $192 million cash (including a $23 million shareholder loan repayment within six months) plus up to $113 million in contingent cash payments tied to gold price over 2.5 years and resource conversions over 5 years. Proceeds will be used to strengthen Barrick’s balance sheet. Closing is expected in late 2025, subject to customary conditions including Government of Côte d’Ivoire approval.

Helzberg, a Berkshire Hathaway company (NYSE: BRK), released its 2025 Engagement & Ring Shopping Survey revealing key trends in modern proposals and ring shopping behaviors. The study, surveying 1,000 U.S. adults aged 20-40, found that 83% prefer private proposals, despite 88% planning to share ring preferences beforehand.

The survey highlighted significant generational differences, with Gen Z showing stronger engagement in social media research (79% vs. 63% millennials) and sustainability concerns (88% vs. 81%). Notable findings include an average maximum ring budget of $4,000, with 76% willing to invest more for customization. While 83% value in-store purchasing options, 56% consider online buying important, reflecting evolving shopping preferences.

Barrick Mining Corporation (NYSE:B) announced a significant leadership transition with the immediate appointment of Mark Hill as Group COO and Interim President & CEO, following Mark Bristow's departure after nearly seven years at the helm.

Hill, currently overseeing Barrick's Latam and Asia Pacific regions, brings 30 years of mining industry experience. Under Bristow's leadership since the 2019 Randgold merger, Barrick has returned $6.7 billion to shareholders and reduced net debt by $4 billion. The Board's Search Committee, led by Brett Harvey, has initiated a search for a permanent CEO with support from a leading executive search firm.